Matthew M. Heeney , MD
Office Phone: 617-355-7700
Appointment Line: 617-355-8246 (Ext. 2)
sickle cell disease
Assistant Professor of Pediatrics, Harvard Medical School
Pediatrics, Pediatric Hematology/Oncology
Trinity College, University of Toronto, Toronto, Canada (1992)
University of Calgary, Calgary, Canada (1995)
Montreal Children's Hospital, McGill University, Montreal, Canada (1995-1999)
Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC (1999-2002)
Bunn HF, Heeney MM.
Iron Homeostasis: Deficiency and Overload. , 2010
Pathophysiology of Blood Disorders Issue: 1st Edition (Bunn HF, Aster JC Editors) , Page: 51-62
New York: McGraw Hill
Heeney MM. Andrews NC.
Iron Homeostasis and Inherited Iron Overload Disorders: An overview. , 2004
Hematology/Oncology Clinics of North America. Issue: 18 (6) , Page: 1379-403
Iron Deficiency Anemia: Definition, Pathophysiology and Classification. , 2011
Rudolph's Pediatrics Issue: 22nd Edition (Rudolph AM, Rudolph C, First L, Lister G, Gershon AA. Editors) , Page: 1546-1548
New York: McGraw Hill
Anemia: Definition, Pathophysiology and Classification. , 2011
Rudolphs Pediatrics Issue: 22nd Edition (Rudolph AM, Rudolph C, First L, Lister G, Gershon AA. Editors) , Page: 1542-1546
New York: McGraw-Hill
Heeney MM. Whorton MR. Howard TA. Johnson CA. Ware RE.
Chemical and Functional Analysis of Hydroxyurea Oral Solutions , 2004
Journal of Pediatric Hematology/Oncology Issue: 26 (3) , Page: 179-184
Heeney MM. Howard TA. Zimmerman SA. Ware RE.
. UGT1A Promoter Polymorphisms Influence Bilirubin Response Hydroxyurea Therapy in Sickle Cell Anemia. , 2003
Journal of Laboratory and Clinical Medicine Issue: 141 (4) , Page: 279-282
Finberg KE. Heeney MM. Campagna DR. Aydinok Y. Pearson HA. Hartman KR. Mayo MM. Samuel SM. Strouse JJ. Markianos K. Andrews NC. Fleming MD.
Mutations in TMPRSS6 cause iron-refractory iron deficiency Anemia (IRIDA). , 2008
Nature Genetics Issue: 40 (5) , Page: 485-682
Dover GJ. Heeney MM.
Sickle Cell Disease , 2008
Nathan and Oskis Hematology of Infancy and Childhood Issue: 7th Edition (Nathan DG, Orkin SH, Ginsburg D, Look AT. Editors) , Page: 949-1014
Philadelphia: WB Saunders
Steinberg MH. Ohene-Frempong K. Heeney MM.
Clinical and Pathophysiological Aspects of Sickle Cell Anemia. , 2009
Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Editors) Issue: 2nd Edition , Page: 437-496
Cambridge: Cambridge University Press
Heeney MM, Ware RE.
Hydroxyurea for Children with Sickle Cell Disease. , 2010
Hematology/Oncology Clinics of North America Issue: 24 (1) , Page: 199-214
Dr. Heeney conducts clinical research focused on sickle cell disorders and their treatment. He has been the Children's Hospital Boston Principal Investigator (PI) for the Boston Comprehensive Sickle Cell Center (CSCC)and the Boston Sickle Cell Disease Research Network (SCDCRN). He is the CHB PI and for the multicenter SWiTCH and TWiTCH trials which are exploring the use of Hydroxyurea as an alternative to chronic transfusion for stroke prevention. Dr. Heeney also conducts translational research in inherited disorders of iron homeostasis in humans. In particular he is interested in investigating the genetic basis inherited disorders of iron deficiency, sideroblastic anemia and iron overload. Goals of Dr. Heeney's work include: to improve the understanding of the pathophysiology and treatment of sickle cell anemia through multicenter clinical trials and to elucidate the genetic basis of iron homeostasis and its role in human disease.
Research site for Matthew Heeney, MD
Children's Hospital BostonPediatric Hematology/Oncology300 Longwood AvenueFegan 702Boston, MA 02115Phone: 617-355-7700Fax: 617-730-0641